BIOSENSE WEBSTER INC NAVISTAR® RMT THERMOCOOL® ELECTROPHYSIOLOGY CATHETER; CATHETER, PERCUTANEOUS, CARDIAC ABLATION, FOR TREATMENT OF ATRIAL FLUTTER
|
Back to Search Results |
|
Model Number NR7TCSIY |
Device Problem
Patient Device Interaction Problem (4001)
|
Patient Problem
Cardiac Tamponade (2226)
|
Event Date 05/19/2022 |
Event Type
Injury
|
Manufacturer Narrative
|
Device investigation details: available information indicates that the device is not available for return, therefore no product investigation can be performed, and the customer complaint cannot be confirmed.A device history record evaluation was performed for the finished device 30740341m number, and no internal action related to the complaint was found during the review.This report is being submitted pursuant to the provisions of 21 cfr, part 4.This report may be based on information which has not been investigated or verified prior to the required reporting date.This report does not reflect a conclusion by biosense webster inc., or its employees that the report constitutes an admission that the product, biosense webster inc., or its employees caused or contributed to the potential event described in this report.If information is obtained that was not available for the initial report, a follow-up report will be filed as appropriate.If additional information is received regarding this event, a supplemental 3500a report will be submitted to the fda.Manufacturer's ref.# (b)(4).
|
|
Event Description
|
It was reported that a (b)(6) year-old male patient ((b)(6) kg) underwent a cardiac ablation procedure with a navistar® rmt thermocool® electrophysiology catheter and the patient suffered cardiac tamponade requiring a pericardiocentesis, surgical intervention and prolonged hospitalization.The cardiac tamponade was noticed right after procedure.The procedure has been successfully completed.The patient required surgery for the cardiac tamponade.The physician¿s opinion on the cause of this adverse event is that it was procedure related.Draining from epicardial space was also performed.The patient outcome of the adverse event was improved.The patient required extended hospitalization because of the adverse event.Activated clotting time (act) range was 257-306 during the procedure.Heparin 12000 iu after transseptal, total 23000 iu during procedure.A smartablate generator was used during this case.A transseptal puncture was performed with an abbott brk-1, 407201.There was no evidence of steam pop.The irrigated catheter flow setting was set to 2/17 ml.The correct catheter settings were selected on the smartablate generator and the pump switching from low to high flow during ablation.
|
|
Manufacturer Narrative
|
On 8-jul-2022, additional information was received which indicated pericardium puncture was performed to drain the pericardial space; no open-heart surgery.Based on this new information, please consider the 6.Health effect - impact code of ¿surgical interventions¿ (f19) to be removed.If additional information is received regarding this event, a supplemental 3500a report will be submitted to the fda.Manufacturer's ref.# (b)(4).
|
|
Search Alerts/Recalls
|
|
|